Purdue student venture fund invests in Kylin Therapeutics

Purdue University’s Student-Managed Venture Fund is betting its bank on West Lafayette-based biotech startup Kylin Therapeutics

This month, MBA students in the Krannert Graduate School of Management invested $100,000 in Kylin, which represents 77 percent
of their fund’s total assets. Kylin, in the Purdue Research Park, is in the preclinical stage of commercializing a technology
to target and "turn off" diseasecausing genes.

Including the student’s investment, Kylin last month raised $2 million in a venture capital round led by West Lafayette-based
In-vivo Ventures and Durham, N.C.-based Golden Pine Ventures. The company plans to use the money to advance its cancer therapy
to the marketplace.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.